Literature DB >> 17142116

Characterization of protein aggregation: the case of a therapeutic immunoglobulin.

Barthélemy Demeule1, M Jayne Lawrence, Alex F Drake, Robert Gurny, Tudor Arvinte.   

Abstract

In this paper, a therapeutic immunoglobulin (Antibody A) has been characterized in two solutions: (1) 0.1% acetic acid containing 50 mM magnesium chloride, a solution in which the immunoglobulin is stable, and (2) 10 mM sodium phosphate buffer pH approximately 7. The protein solutions were characterized by microscopy, asymmetrical flow field-flow fractionation (FFF), light scattering, circular dichroism, fluorescence and fluorescence lifetime spectroscopy. The results show that Antibody A dissolved in 0.1% acetic acid containing 50 mM magnesium chloride exists as 88% monomer, 2% low molecular weight aggregates and 10% high molecular weight aggregates (>1 million Dalton). In phosphate buffer, Antibody A formed micrometre-sized aggregates that were best characterized by fluorescence microscopy. The aggregation of Antibody A in phosphate buffer was shown to be concomitant with conformational changes in amino acid residue side chains. The aggregates formed in phosphate buffer were easily disrupted during FFF analysis, indicating that they are formed by weak interactions. The combination of microscopy, asymmetrical flow field-flow fractionation (FFF) and spectroscopy allowed a reliable assessment of protein self association and aggregation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17142116     DOI: 10.1016/j.bbapap.2006.10.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  18 in total

1.  Phase separation of an IgG1 antibody solution under a low ionic strength condition.

Authors:  Hirotaka Nishi; Makoto Miyajima; Hiroaki Nakagami; Masanori Noda; Susumu Uchiyama; Kiichi Fukui
Journal:  Pharm Res       Date:  2010-04-17       Impact factor: 4.200

2.  Modifications of therapeutic proteins: challenges and prospects.

Authors:  Nigel Jenkins
Journal:  Cytotechnology       Date:  2007-05-25       Impact factor: 2.058

3.  Conformational stability and aggregation of therapeutic monoclonal antibodies studied with ANS and Thioflavin T binding.

Authors:  Veysel Kayser; Naresh Chennamsetty; Vladimir Voynov; Bernhard Helk; Bernhardt L Trout
Journal:  MAbs       Date:  2011-07-01       Impact factor: 5.857

4.  The effects of excipients and particle engineering on the biophysical stability and aerosol performance of parathyroid hormone (1-34) prepared as a dry powder for inhalation.

Authors:  Sunday A Shoyele; Neeraj Sivadas; Sally-Ann Cryan
Journal:  AAPS PharmSciTech       Date:  2011-01-27       Impact factor: 3.246

5.  Effect of homocysteine thiolactone on structure and aggregation propensity of bovine pancreatic insulin.

Authors:  Shima Jalili; Reza Yousefi; Mohammad-Mehdi Papari; Ali Akbar Moosavi-Movahedi
Journal:  Protein J       Date:  2011-06       Impact factor: 2.371

6.  FTIR markers of methionine oxidation for early detection of oxidized protein therapeutics.

Authors:  Jascindra Ravi; Anna E Hills; Eleonora Cerasoli; Paulina D Rakowska; Maxim G Ryadnov
Journal:  Eur Biophys J       Date:  2011-01-13       Impact factor: 1.733

7.  A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1.

Authors:  Camilla De Nardis; Linda J A Hendriks; Emilie Poirier; Tudor Arvinte; Piet Gros; Alexander B H Bakker; John de Kruif
Journal:  J Biol Chem       Date:  2017-06-27       Impact factor: 5.157

8.  Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin (bevacizumab), Remicade (infliximab) and Herceptin (trastuzumab).

Authors:  Bas J M Peters; Martinus A H Capelle; Tudor Arvinte; Ewoudt M W van de Garde
Journal:  MAbs       Date:  2012-12-19       Impact factor: 5.857

9.  Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice.

Authors:  Vasco Filipe; Wim Jiskoot; Abdul Hafid Basmeleh; Andhyk Halim; Huub Schellekens; Vera Brinks
Journal:  MAbs       Date:  2012-09-05       Impact factor: 5.857

10.  Size-Exclusion Chromatography for the Analysis of Protein Biotherapeutics and their Aggregates.

Authors:  Paula Hong; Stephan Koza; Edouard S P Bouvier
Journal:  J Liq Chromatogr Relat Technol       Date:  2012-11-30       Impact factor: 1.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.